Is LH a Buy? What to Consider in 2026

Last updated July 2026

Short answer

The bull case for Labcorp Holdings (LH) rests on Recurring diagnostics volume and scale: Labcorp Diagnostics processes an enormous, recurring stream of routine and specialty tests, which gives the company predictable demand that is relatively insulated from the economic cycle. Revenue (FY2025) is ~$13.95 billion. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Labcorp's biggest risk is reimbursement pressure, since a large share of revenue depends on rates set by Medicare, Medicaid, and commercial payers, and legislated fee cuts under frameworks like PAMA can compress pricing. Whether LH is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.

Labcorp Holdings is a leading US healthcare diagnostics company that runs clinical laboratory tests for physicians, hospitals, health systems, and patients, and also provides laboratory services to pharmaceutical and biotech firms running clinical trials. Its two reporting segments are Labcorp Diagnostics, the routine and specialty testing business that processes millions of patient samples, and Labcorp Biopharma Laboratory Services, which supports drug development with central-lab and early-development testing. Alongside domestic rival Quest Diagnostics, Labcorp is one of the two dominant independent lab networks in the country. The company spun off its clinical-trial contract-research organization, Fortrea, in 2023 to focus on core testing. The investment picture is that of a defensive, cash-generative healthcare company rather than a high-growth name. Full-year 2025 revenue was about $13.95 billion with net income near $877 million, and management raised 2026 guidance to roughly $14.6 billion to $14.8 billion in revenue and adjusted EPS of about $17.70 to $18.35. Growth comes from mid-single-digit organic testing gains, tuck-in acquisitions of hospital outreach labs, specialty and genomic test menus, and steady biopharma demand, while free cash flow funds a dividend and share buybacks. The trade-off is exposure to reimbursement rates, payer mix, and regulatory pricing that can cap the upside.

What's the case for buying LH?

1. Recurring diagnostics volume and scale.

Labcorp Diagnostics processes an enormous, recurring stream of routine and specialty tests, which gives the company predictable demand that is relatively insulated from the economic cycle. In Q1 2026 the Diagnostics segment grew about 5.0% with improving margins. Scale advantages in logistics, automation, and payer contracts are hard for smaller labs to match.

2. Hospital-lab acquisitions and outreach deals.

A core part of Labcorp's strategy is acquiring hospital and health-system outreach lab businesses and managing lab operations under long-term agreements. These tuck-in deals add volume and geographic density without building new infrastructure from scratch. Because hospital labs still control more than half of US testing volume, this pipeline is a durable growth avenue.

3. Biopharma laboratory services.

The Labcorp Biopharma Laboratory Services segment supports drug developers with central-lab and early-development testing tied to clinical trials, and it grew about 8.2% in Q1 2026. This arm diversifies revenue beyond routine patient testing and links Labcorp to pharma and biotech research budgets. Demand here tracks industry R&D spending and clinical-trial activity.

4. Margin expansion and capital returns.

Management is targeting adjusted operating-margin improvement through automation, its Launchpad efficiency program, and menu mix toward higher-value specialty and genomic tests. Free cash flow funds a dividend and buybacks, including completion of a multi-year repurchase program in early 2026. Raised 2026 adjusted EPS guidance of roughly $17.70 to $18.35 reflects this combination of growth and cost discipline.

What are the risks to LH?

Labcorp's biggest risk is reimbursement pressure, since a large share of revenue depends on rates set by Medicare, Medicaid, and commercial payers, and legislated fee cuts under frameworks like PAMA can compress pricing. Payer mix and volume shifts, including the rise of at-home and point-of-care testing, could erode walk-in and routine-test revenue over time. The business is capital and labor intensive, so wage inflation and integration costs from acquisitions can weigh on margins. Biopharma demand is tied to pharma R&D budgets and clinical-trial activity, which can soften in a funding downturn. Regulatory changes around laboratory-developed tests and ongoing competition from Quest Diagnostics and hospital systems add further uncertainty.

How is LH valued? (as of JULY 2026)

Price

$296.77

Market cap

$24.34B

P/E (TTM)

26.31

Forward P/E

15.29

Price / book

2.80

Beta

0.86

52-week range

$244.52 to $298.58

Snapshot for LH as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (FY2025): ~$13.95 billion
Revenue guidance (FY2026): ~$14.6-14.8 billion
Net income (FY2025): ~$877 million
Adjusted EPS guidance (FY2026): ~$17.70-18.35
Market cap: ~$24 billion
P/E (trailing / forward): ~26x / ~16x

As of July 2026 Labcorp traded near $296 per share for a market cap around $24 billion, close to a 52-week high. The trailing P/E near 26x compresses to roughly 16x on 2026 adjusted EPS guidance, a valuation that sits below many healthcare peers. That reflects steady mid-single-digit revenue growth rather than rapid expansion, plus a modest dividend and buyback program.

How do you decide if LH is a buy?

Rather than asking whether LH is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold LH indirectly through an index or sector ETF before adding more.

For the full picture, see the LH stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about LH against your real portfolio and see your actual exposure before deciding.

The bottom line on LH

The bottom line: Labcorp Holdings's story right now is Recurring diagnostics volume and scale, with revenue (fy2025) at ~$13.95 billion. If you believe that narrative continues, the call is about sizing LH sensibly and checking overlap with what you own; if you doubt it (the risk: labcorp's biggest risk is reimbursement pressure, since a large share of revenue depends on rates set by Medicare, Medicaid, and commercial payers, and legislated fee cuts under frameworks like PAMA can compress pricing.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.

More on LH

LH stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
LH stock forecast (the drivers and risks shaping the outlook)
Does LH pay a dividend?

Build a basket around LH with Walnut

Use Labcorp Holdings as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.

Create a free Walnut account

FAQ

Is LH a good stock to buy right now?

The case for Labcorp Holdings right now is Recurring diagnostics volume and scale, with revenue (fy2025) at ~$13.95 billion. If you believe that thesis holds, LH is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is labcorp's biggest risk is reimbursement pressure, since a large share of revenue depends on rates set by Medicare, Medicaid, and commercial payers, and legislated fee cuts under frameworks like PAMA can compress pricing. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.

What does Labcorp Holdings do?

Labcorp Holdings is a leading US healthcare diagnostics company that runs clinical laboratory tests for physicians, hospitals, health systems, and patients, and also provides labor

What are the main risks of LH?

What does Labcorp do?

Labcorp runs clinical laboratory tests for doctors, hospitals, and patients through its Diagnostics segment, and provides central-lab and early-development testing for drug developers through its Biopharma Laboratory Services segment. It is one of the two largest independent lab networks in the United States.

What is Labcorp's ticker and where is it listed?

Labcorp Holdings trades under the ticker LH on the New York Stock Exchange (NYSE). It is a large-cap US healthcare company and a component of major indexes including the S&P 500.

How does Labcorp make money?

The majority of revenue comes from routine and specialty clinical testing reimbursed by Medicare, Medicaid, and commercial insurers, plus patient payments. A meaningful additional slice comes from biopharma lab services tied to clinical trials and drug development.

How big is Labcorp?

Labcorp reported about $13.95 billion in revenue for full-year 2025 and guides to roughly $14.6 to $14.8 billion for 2026. As of July 2026 its market capitalization was around $24 billion.

Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell LH; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.